Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016', provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics. The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - The report reviews Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview 7 Therapeutics Development 8 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development 8 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area 9 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication 10 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies 13 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development 20 Ablynx NV 20 Amgen Inc. 21 Apogenix GmbH 22 Bristol-Myers Squibb Company 23 Five Prime Therapeutics, Inc. 24 Incyte Corporation 25 MedImmune, LLC 26 Merck & Co., Inc. 27 Novartis AG 28 OncoMed Pharmaceuticals, Inc. 29 Regeneron Pharmaceuticals, Inc. 30 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles 31 AMG-228 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BMS-986156 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 FPA-154 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 GWN-323 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 INCAGN-1876 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 LKZ-145 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MEDI-1873 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 MK-1248 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MK-4166 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Recombinant Protein to Agonize GITR for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 TRX-518 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases 48 Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting 48 Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 48 Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 49 Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 50 Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference 50 Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 51 Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518 52 Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer 53 Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518 54 Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer 54 Oct 21, 2008: Laureate To Manufacture Tolerx's TRX518 Antibody 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 56 Disclaimer 57
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Ablynx NV, H1 2016 20 Pipeline by Amgen Inc., H1 2016 21 Pipeline by Apogenix GmbH, H1 2016 22 Pipeline by Bristol-Myers Squibb Company, H1 2016 23 Pipeline by Five Prime Therapeutics, Inc., H1 2016 24 Pipeline by Incyte Corporation, H1 2016 25 Pipeline by MedImmune, LLC, H1 2016 26 Pipeline by Merck & Co., Inc., H1 2016 27 Pipeline by Novartis AG, H1 2016 28 Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 29 Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.